• PhilPapers
  • PhilPeople
  • PhilArchive
  • PhilEvents
  • PhilJobs
  • Sign in
PhilPeople
 
  • Sign in
  • News Feed
  • Find Philosophers
  • Departments
  • Radar
  • Help
 
profile-cover
Drag to reposition
profile picture

David Magnus

Stanford University
  •  Home
  •  Publications
    88
    • Most Recent
    • Most Downloaded
    • Topics
  •  News and Updates
    9

 More details
  • Stanford University
    Department of Philosophy
    Unknown
Stanford, California, United States of America
  • All publications (88)
  •  85
    The Modeling of Nature: Philosophy of Science and Philosophy of Nature in Synthesis by William A. Wallace (review)
    with Monique Bourque
    Isis 89 372-373. 1998.
    Aristotle: Philosophy of ScienceGeneral Philosophy of Science, Misc
  •  145
    Stem cell research: The california experience
    Hastings Center Report 36 (1): 26-28. 2006.
    Stem Cell Research
  • Lock Out'Back Door Eugenics.'
    Penn Bioethics, 3 (1). forthcoming.
    Eugenics
  •  73
    CPR and Ventricular Assist Devices: The Challenge of Prolonging Life Without Guaranteeing Health
    with Danton Char
    American Journal of Bioethics 17 (2): 1-2. 2017.
    Biomedical Ethics
  •  63
    Sexless Reproduction: A Status Symbol
    with Molly Havard
    American Journal of Bioethics 11 (3): 1-1. 2011.
    This Article does not have an abstract
    Biomedical Ethics
  •  86
    Translating Stem Cell Research: Challenges at the Research Frontier
    Journal of Law, Medicine and Ethics 38 (2): 267-276. 2010.
    There are many kinds of clinical trials. The regulatory framework within which most drug development takes place appears to be the one that is to be applied to the development of novel stem cell-based clinical trials. In the standard drug development model, appropriate pre-clinical research is conducted, and investigators or research sponsors submit an investigational new drug application to the Food and Drug Administration.If approved, typical clinical trials start with Phase I, which is usuall…Read more
    There are many kinds of clinical trials. The regulatory framework within which most drug development takes place appears to be the one that is to be applied to the development of novel stem cell-based clinical trials. In the standard drug development model, appropriate pre-clinical research is conducted, and investigators or research sponsors submit an investigational new drug application to the Food and Drug Administration.If approved, typical clinical trials start with Phase I, which is usually a trial to determine the maximum tolerable dose of a drug. Phase I trials are often referred to as “safety studies” because the primary goal of Phase I research is to determine if an intervention is safe.
    Stem Cell Research
  •  105
    The History of The American Journal of Bioethics
    American Journal of Bioethics 10 (10): 3-3. 2010.
    This Article does not have an abstract
    Biomedical Ethics
  •  49
    Playing it safe
    American Journal of Bioethics 7 (3). 2007.
    This Article does not have an abstract
    Biomedical Ethics
  •  87
    Family problems
    with Lisa Dagostino
    American Journal of Bioethics 1 (3): 1. 2001.
    Biomedical Ethics
  •  108
    Blood, sweat and tears
    American Journal of Bioethics 6 (3). 2006.
    This Article does not have an abstract
    Biomedical Ethics
  •  143
    The J. H. B. bookshelf
    with Sara F. Tjossem, Vassiliki Betty Smocovitis, Paul Lawrence Farber, Joel B. Hagen, and Jean-Paul Gaudilli´re
    Journal of the History of Biology 29 (1): 145-154. 1996.
    History of BiologyPhilosophy of Biology, Misc
  •  92
    The Instrumental Role of Hospital Ethics Committees in Policy Work
    with Nanibaa’ A. Garrison
    American Journal of Bioethics 12 (11): 1-2. 2012.
    No abstract
    Biomedical EthicsMedical EthicsPublic Health, Misc
  •  87
    Theory, practice, and epistemology in the development of species concepts
    Studies in History and Philosophy of Science Part A 27 (4): 521-545. 1996.
    Science, Logic, and MathematicsSpecies ConceptsEpistemology of Specific Domains, Misc
  •  49
    Stem Cell Research Should Be More Than a Promise
    Hastings Center Report 34 (5): 35-36. 2004.
    Biomedical EthicsReproductive Ethics
  •  57
    Organizational Needs Versus Ethics Committee Practice
    American Journal of Bioethics 9 (4): 1-2. 2009.
    No abstract
    Biomedical EthicsPublic Health, Misc
  •  96
    Clinical Ethics Consultation: A Need for Evidence
    American Journal of Bioethics 15 (1): 1-2. 2015.
    Biomedical EthicsMedical Ethics
  •  105
    A Commentary on Oocyte Donation for Stem Cell Research in South Korea
    with Mildred K. Cho
    American Journal of Bioethics 6 (1). 2006.
    No abstract
    Stem Cell Research
  •  132
    Can Informed Consent Go Too Far? Balancing Consent and Public Benefit in Research
    with Lauren C. Milner
    American Journal of Bioethics 13 (4). 2013.
    (2013). Can Informed Consent Go Too Far? Balancing Consent and Public Benefit in Research. The American Journal of Bioethics: Vol. 13, No. 4, pp. 1-2. doi: 10.1080/15265161.2013.778645
    Biomedical EthicsInformed Consent in Medicine
  •  125
    Genomic Contraindications for Heart Transplantation
    with Danton S. Char, Gabriel Lázaro-Muñoz, Aliessa Barnes, Michael J. Deem, and John D. Lantos
    Pediatrics 139 (4). 2017.
    Organ TransplantationDisability RightsInformed Consent in MedicineBeneficence in Medical Ethics
  •  44
    100th Issue Anniversary Editorial
    American Journal of Bioethics 13 (1): 1-2. 2013.
    No abstract
    Biomedical Ethics
  •  82
    Professional Judgment and Justice: Equal Respect for the Professional Judgment of Critical-Care Physicians
    with Norm Rizk
    American Journal of Bioethics 16 (1): 1-2. 2016.
    Biomedical Ethics
  •  45
    Finding the Right Tools for Assessing Quality of Clinical Ethics Consultation
    American Journal of Bioethics 16 (3): 1-2. 2016.
    Biomedical EthicsMedical Ethics
  •  67
    Beyond the IRB: Local Service Versus Global Oversight
    with Molly Havard
    American Journal of Bioethics 11 (5): 1-2. 2011.
    Biomedical EthicsMedical Ethics
  •  141
    Can the Dead Donor Rule be Resuscitated?
    with Simone Lucia Vernez
    American Journal of Bioethics 11 (8): 1-1. 2011.
    The American Journal of Bioethics, Volume 11, Issue 8, Page 1, August 2011
    Biomedical EthicsMedical Ethics
  •  64
    Innocent Fun or “Microslavery”?
    with Hayden Harvey, Molly Havard, Mildred K. Cho, and Ingmar H. Riedel-Kruse
    Hastings Center Report 44 (6): 38-46. 2014.
    In 2011, Ingmar Riedel‐Kruse's bioengineering laboratory at Stanford University publicized an application that uses paramecia for what the researchers termed “biotic games.” These games make use of living organisms, computer programs, and lab equipment to implement games like Pong, Pac‐man, and soccer. Gamesand related activities are often considered nonserious or trivial, whereas life, biological systems, and science are treated very seriously in moral analysis and public perception. The manipu…Read more
    In 2011, Ingmar Riedel‐Kruse's bioengineering laboratory at Stanford University publicized an application that uses paramecia for what the researchers termed “biotic games.” These games make use of living organisms, computer programs, and lab equipment to implement games like Pong, Pac‐man, and soccer. Gamesand related activities are often considered nonserious or trivial, whereas life, biological systems, and science are treated very seriously in moral analysis and public perception. The manipulation of living matter frequently engenders at least some controversy in the marketplace of ideas, and using living things in games is no exception. Some of the objections lodged against biotic games have appeared in the ethics literature on similar topics; however, the addition of an entertainment element introduces some objections distinct from those about similar cases, as the online comments vividly illustrate. We aim to explore and address the objections in this paper, using the comments to organize and launch the discussion. In scientific work, there is typically a presumption of some prospect of translation and application of generated knowledge for public benefit. In the case of biotic games, these applications are not self‐evident. Because of this, a serious analysis of the justifications, limitations, and features of biotic games is warranted. To this end, we outline key ethical limits that ought to be placed on these activities as well as the obligations that these activities generate for researchers, other professionals, and lay people who design, implement, use, and play them.
    Biomedical Ethics
  •  70
    The Proper Locus of Professionalization: The Individual or the Institutions?
    with Bela Fishbeyn
    American Journal of Bioethics 15 (5): 1-2. 2015.
    Biomedical Ethics
  •  98
    The concept of genetic disease
    In Arthur L. Caplan, James J. McCartney & Dominic A. Sisti (eds.), Health, Disease, and Illness: Concepts in Medicine, Georgetown University Press. pp. 233--42. 2004.
    The Concept of Disease
  •  95
    Overthrowing the Tyranny of the Journal Impact Factor
    American Journal of Bioethics 13 (7): 1-2. 2013.
    No abstract
    Biomedical EthicsPsychopathology
  • Prev.
  • 1
  • 2
  • 3
  • Next
PhilPeople logo

On this site

  • Find a philosopher
  • Find a department
  • The Radar
  • Index of professional philosophers
  • Index of departments
  • Help
  • Acknowledgments
  • Careers
  • Contact us
  • Terms and conditions

Brought to you by

  • The PhilPapers Foundation
  • The American Philosophical Association
  • Centre for Digital Philosophy, Western University
PhilPeople is currently in Beta Sponsored by the PhilPapers Foundation and the American Philosophical Association
Feedback